

◆ Department of Continuing Medical Education ◆

Conflict of Interest Disclosure and Resolution & Core Competencies
11th Annual Clinical Cancer Genetics and Genomics Conference

*From Precision Medicine to Precision Prevention:
 Joining Forces Across the Spectrum of Care*

May 5 - 7, 2023

CONFLICT OF INTEREST DISCLOSURE AND RESOLUTION

City of Hope takes responsibility for the content, quality and scientific integrity of this CME activity.

City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME). As a fully accredited ACCME Category 1 CME credit provider, the Continuing Medical Education Department has in place policies and procedures which insure the balance, independence, objectivity and scientific rigor in all of its educational activities. City of Hope complies with the [Standards for Integrity and Independence in Accredited Continuing Education](#) of the (ACCME), which REQUIRE that all relevant disclosed conflicts of interest be mitigated prior to the educational activity.

To this end all faculty presenters who are in a position to control the content of an educational activity must identify any real or apparent conflict(s) of interest by disclosing to the Department of CME all relevant financial relationships¹ with any ineligible company². To comply with more intense scrutiny by accreditation agencies, should you disclose any relevant conflict of interest with an ineligible company, the content of your presentation must be peer reviewed prior to presenting. Presentations will be provided to participants as an e-syllabus or in a meeting handout, all relevant disclosures will be made known to participants prior to the start of the activity.

In furtherance of program impartiality, we request the use of generic drug names in your presentation as opposed to trade names. Under no circumstances will we accept trade names. Additionally, contents of your presentation must be based solely on scientific methods generally accepted by the medical community. Data will have been objectively selected from peer-reviewed literature and will be presented in an unbiased manner.

CORE COMPETENCIES

The American Board of Medical Specialties (ABMS) and the Accreditation Council of Graduate Medical Education (ACGME) have embarked on a joint initiative to quantify and evaluate a set of 6 physician core competencies by which the individual physician will be measured for Residency Certification, Board Certification and more recently, Maintenance of Certification (MOC). Individual hospitals and other health care delivery organizations will now also be evaluated by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) on their practice and demonstration of the 6 core competencies.

In brief, the actual term “core competencies” refers to those six abilities (competencies) that are central (core) to the practice of medicine, specifically: (1) Practice-Based Learning and Improvement, (2) Patient Care, (3) Systems-Based Practice, (4) Medical Knowledge, (5) Interpersonal and Communication Skills, and (6) Professionalism. To assist our conferees in demonstrating their completion of CME in the six core competencies, the educational content of each presentation will be noted by numbers 1-6 in the table below. CME certificates for this activity will reflect those core competencies addressed by the educational content of the overall conference.

Conference Faculty	Commercial Interest	Conflict/Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Amie Blanco, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Kathleen R. Blazer, EdD, MS	Grant/Research Support from Pfizer.	Attestation on file – No conflict noted	None
Carol A. Burke, MD	Grant/Research Support from Emtora Biosciences, Freenome, Inc., and Janssen; Consultant for Janssen, Sebela Pharmaceuticals, and SLA Pharma; On the Speakers Bureau for Amby Genetics.	Attestation on file – No conflict noted	4
Yanin Chavarri-Guerra, MD, MSc	Grant/Research Support from Roche; Consultant for AstraZeneca; On the Speakers Bureau for Invitae; Travel Funding for AstraZeneca, and Novartis.	Attestation on file – No conflict noted	1 & 3
Heather H. Cheng, MD, PhD	Grant/Research Support from Astellas, Clovis Oncology, Color Health, Janssen, Medivation, and Promontory Therapeutics; Consultant for AstraZeneca; Other financial/material interests from UpToDate (Royalties).	Attestation on file – No conflict noted	1, 2, 3 & 4

Conference Faculty	Commercial Interest	Conflict/Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Vincent Chung, MD	On the Speakers Bureau for AstraZeneca & Ipsen; Consultant for Perthera.	Attestation on file – No conflict noted	4
Jane E. Churpek, MD, MS	Other financial/material interests in UpToDate, Inc. (honoraria for educational article).	Attestation on file – No conflict noted	1, 2, 3, 4, 5 & 6
Sandra Dreike, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Rowan Forbes Shepherd, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	5 & 6
Alexea M. Gaffney-Adams, MD	Consultant for Abbvie; On the Speakers Bureau for Gilead Sciences, Inc.	Attestation on file – No conflict noted	2, 5 & 6
Lauren Gima, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Dena Goldberg, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None	5
Stacy W. Gray, MD, AM	Consultant for Harvard Medical School, Department of Health Care Policy.	Attestation on file – No conflict noted	1, 2, 3 & 4
Stephen Gruber, MD, PhD	Grant/Research Support from Abbvie, AstraZeneca, Eisai, Genivo, Inc., and Invitae; Co-Founder of Brogent International, LLC.	Attestation on file – No conflict noted	1, 2, 3, 4, 5 & 6
Michael J. Hall, MD, MS	Consultant for Eisai, and Natera.	Attestation on file – No conflict noted	2, 5 & 6
Heather Hampel, MS, CGC	Consultant for 23andMe, AIM Specialty Health, Genome Medical, GI OnDemand, Invitae, Natera, and Promega; Stock/Shareholder of Genome Medical, and GI OnDemand.	Attestation on file – No conflict noted	1, 3 & 4
Gregory Idos, MD, MS	I do not have any relevant financial relationships with any ineligible companies.	None	2 & 4
Leila Jamal, ScM, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	2, 3 & 5
Allison W. Kurian, MD, MSc	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Daneng Li, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Reviewer
Rachelle Manookian, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None	1 & 4
Kara N. Maxwell, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6

Conference Faculty	Commercial Interest	Conflict/Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Kevin McDonnell, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	4
Paige More	I do not have any relevant financial relationships with any ineligible companies.	None	2, 5 & 6
Joanne Mortimer, MD	Grant/Research Support from AstraZeneca, and Daiichi Sankyo; Consultant for Novartis, and Pfizer.	Attestation on file – No conflict noted	1, 2, 3 & 4
Bitu Nehoray, MS, CGC	Consultant for Invitae.	Attestation on file – No conflict noted	1, 2, 4, 5 & 6
Olufunmilayo Olopade, MD	Consultant for 54Gene, and Tempus; Stock/Shareholder of CancerIQ.	Attestation on file – No conflict noted	1, 3, 4 & 5
Rena J. Pasick, DrPH	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3 & 5
Colin C. Pritchard MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Padma S. Rajagopal, MD, MPH	I do not have any relevant financial relationships with any ineligible companies.	None	2 & 4
Gad Rennert, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	4, 5 & 6
Iris Romero, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Allison Rosen, MS	Consultant for Bayer, and Exact Sciences.	Attestation on file – No conflict noted	2, 5 & 6
Crystal Saavedra, BA	I do not have any relevant financial relationships with any ineligible companies.	None	Planner
Ravi Salgia, MD, PhD	Consultant for Abbvie, Inc., AstraZeneca, DAVA Oncology, Iovance Biotheapeutics, Mirati Therapeutics, and Sanofi; On the Speakers Bureau for Merck & Co.	Attestation on file – No conflict noted	1, 3 & 4
N. Jewel Samadder, MD, MSc	Consultant for Guardant Health, and Janssen.	Attestation on file – No conflict noted	1, 2, 3 & 4
Sharon A. Savage, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 4, 5 & 6
Susan Shehayeb, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Elise Sobotka, MSGC, MPH	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Zsofia K. Stadler, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1 & 4
Sapna Syngal, MD, MPH	Other financial/material interests in Myriad Genetics (licensing royalties).	Attestation on file – No conflict noted	1, 2, 3 & 4
Cristian Tomasetti, PhD	Consultant for Bayer, Haystack Oncology, and PrognomiQ; Other financial/material interest from Exact Sciences (Royalties).	Attestation on file – No conflict noted	1 & 4

Conference Faculty	Commercial Interest	Conflict/Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Eduardo Vilar-Sanchez, MD, PhD	Consultant for Janssen Research & Development, and Recursion Pharmaceuticals.	Attestation on file – No conflict noted <i>Off-label/Investigational use of: Use of NSAIDs and vaccine in cancer prevention.</i>	1, 2, 3, 4, 5 & 6
Miguel Villalona-Calero, MD	Consultant for Eli Lilly; On the Speakers Bureau for Amgen.	Attestation on file – No conflict noted	4
Alexi A. Wright, MD, MPH	Grant/Research Support from AstraZeneca, and GlaxoSmithKline; Consultant for GlaxoSmithKline, and Merck.	Attestation on file – No conflict noted	1, 2, 3, 4, 5 & 6
Elyssa Zukin, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6

Planning Committee	Commercial Interest	Conflict/Resolution
Kathleen R. Blazer, EdD, MS	Grant/Research Support from Pfizer.	Attestation on file – No conflict noted
Alexandra Capasso, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None
Anuja Anil Chitre, MS	I do not have any relevant financial relationships with any ineligible companies.	None
Sandra Dreike, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None
Lauren Gima, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None
Stacy W. Gray, MD, AM	Consultant for Harvard Medical School, Department of Health Care Policy.	Attestation on file – No conflict noted
Stephen Gruber, MD, PhD	Grant/Research Support from Abbvie, AstraZeneca, Eisai, Genivo, Inc., and Invitae; Co-Founder of Brogent International, LLC.	Attestation on file – No conflict noted
Heather Hampel, MS, CGC	Consultant for 23andMe, AIM Specialty Health, Genome Medical, GI OnDemand, Invitae, Natera, and Promega; Stock/Shareholder of Genome Medical, and GI OnDemand.	Attestation on file – No conflict noted
Phyllis Leung, Med	I do not have any relevant financial relationships with any ineligible companies.	None
John Martin Louis Cruz Luna, MS	I do not have any relevant financial relationships with any ineligible companies.	None
Rachelle Manookian, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None
Catherine A. Marcum, DNP	I do not have any relevant financial relationships with any ineligible companies.	None
Bitu Nehoray, MS, CGC	Consultant for Invitae.	Attestation on file – No conflict noted
Gloria Nunez, MPH	I do not have any relevant financial relationships with any ineligible companies.	None
Olufunmilayo Olopade, MD	Consultant for 54Gene, and Tempus; Stock/Shareholder of CancerIQ.	Attestation on file – No conflict noted
Iris Romero, MD	I do not have any relevant financial relationships with any ineligible companies.	None

Planning Committee	Commercial Interest	Conflict/Resolution
Susan Shehayeb, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None
Elise Sobotka, MSGC, MPH	I do not have any relevant financial relationships with any ineligible companies.	None
Ilana Solomon, ScM, MA	I do not have any relevant financial relationships with any ineligible companies.	None
Dev Tanna, BS	I do not have any relevant financial relationships with any ineligible companies.	None
Elyssa Zukin, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None

1. The ACCME defines "relevant" financial relationships" as financial relationships with an ineligible company (in any amount), occurring within the past 24 months, that create a conflict of interest.
2. The ACCME defines an "ineligible company" as any entity producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.